Julie Rathbun
Investor Relations Contact chez ATHIRA PHARMA, INC.
Profil
Julie Rathbun is the founder and president of Rathbun Communications, Inc. founded in 2004.
She is currently the Head of Public and Investor Relations at Athira Pharma, Inc. Ms. Rathbun has previously worked as the Head of Investor Relations at Sarepta Therapeutics, Inc., Media Relations Contact at Immune Design Corp., and Media Contact at Neoleukin Therapeutics, Inc. Ms. Rathbun has an undergraduate degree from Western Washington University.
Postes actifs de Julie Rathbun
| Sociétés | Poste | Début |
|---|---|---|
| ATHIRA PHARMA, INC. | Investor Relations Contact | - |
| Rathbun Communications, Inc. | Founder | 01/01/2004 |
Anciens postes connus de Julie Rathbun
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNE DESIGN CORP | Public Communications Contact | 02/04/2019 |
| NEUROGENE INC. | Public Communications Contact | - |
| SAREPTA THERAPEUTICS, INC. | Public Communications Contact | - |
Formation de Julie Rathbun
| Western Washington University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
| Rathbun Communications, Inc. |
